From being the second-largest pharma company by market capitalisation a couple of years ago, Lupin has slipped to sixth position now. The reason for the decline has been severe pricing pressure in the US market, and lack of revenue triggers despite large acquisitions.
Rising competitive intensity and channel consolidation in the US has not only hurt its key diabetes portfolio but also its base business. What has compounded the problems is that acquisitions, such as that of Gavis, have not yielded benefits as expected. In fact, the company had to take a one-time impairment of Rs 14.64 ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
Note: Subscription will be auto renewed, you may cancel any time in the future without any questions asked.
What you get?
ON BUSINESS STANDARD DIGITAL
- Unlimited access to all the content on any device through browser or app.
- Exclusive content, features, opinions and comment – hand-picked by our editors, just for you.
- Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
- Track the industry of your choice with a daily newsletter specific to that industry.
- Stay on top of your investments. Track stock prices in your portfolio.
- 18 years of archival data.
- Requires you to share personal information like date of birth, income, location amongst other fields. This information alongwith your contact information will be shared with the partners associated with this program, who contribute towards subsidizing the offer. By subscribing to this product you acknowledge and accept that our Partners may choose to contact you with offers of their products and services.
- This is an optional offer - Not comfortable with sharing personal data - please opt for the full price offer which requires you to share minimal information